

# Niklaus G Schaefer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7052777/publications.pdf>

Version: 2024-02-01

85  
papers

2,794  
citations

201674

27  
h-index

189892

50  
g-index

91  
all docs

91  
docs citations

91  
times ranked

3613  
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-Hodgkin Lymphoma and Hodgkin Disease: Coregistered FDG PET and CT at Staging and Restagingâ€”Do We Need Contrast-enhanced CT?. <i>Radiology</i> , 2004, 232, 823-829.	7.3	324
2	<i>In Vivo</i> Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548. <i>Clinical Cancer Research</i> , 2013, 19, 5434-5443.	7.0	174
3	Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. <i>Cancer Discovery</i> , 2022, 12, 108-133.	9.4	165
4	New Derivatives of Vitamin B12 Show Preferential Targeting of Tumors. <i>Cancer Research</i> , 2008, 68, 2904-2911.	0.9	117
5	Bone involvement in patients with lymphoma: the role of FDG-PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 60-67.	6.4	113
6	Automatic lesion detection and segmentation of 18F-FET PET in gliomas: A full 3D U-Net convolutional neural network study. <i>PLoS ONE</i> , 2018, 13, e0195798.	2.5	112
7	Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 936-943.	6.4	108
8	<sup>68</sup> Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?. <i>Neuro-Oncology</i> , 2016, 18, 1021-1027.	1.2	80
9	Incidence and Intensity of F-18 FDG Uptake After Vaccination With H1N1 Vaccine. <i>Clinical Nuclear Medicine</i> , 2011, 36, 848-853.	1.3	77
10	Hodgkin Disease: Diagnostic Value of FDG PET/CT after First-Line Therapyâ€”Is Biopsy of FDG-avid Lesions Still Needed?. <i>Radiology</i> , 2007, 244, 257-262.	7.3	71
11	Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. <i>Lung Cancer</i> , 2010, 67, 311-317.	2.0	71
12	Protocol requirements and diagnostic value of PET/MR imaging for liver metastasis detection. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 649-658.	6.4	71
13	Dosimetry and First Clinical Evaluation of the New <sup>18</sup> F-Radiolabeled Bombesin Analogue BAY 864367 in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 372-378.	5.0	70
14	18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1859-1868.	6.4	62
15	Quantitative bone SPECT/CT: high specificity for identification of prostate cancer bone metastases. <i>BMC Musculoskeletal Disorders</i> , 2019, 20, 619.	1.9	48
16	Computed Tomographic Perfusion Imaging for the Prediction of Response and Survival to Transarterial Radioembolization of Liver Metastases. <i>Investigative Radiology</i> , 2013, 48, 787-794.	6.2	42
17	Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT. <i>BMC Cancer</i> , 2015, 15, 1002.	2.6	42
18	Signature of survival: a 18F-FDG PET based whole-liver radiomic analysis predicts survival after 90Y-TARE for hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 4549-4558.	1.8	42

#	ARTICLE	IF	CITATIONS
19	Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?. <i>Annals of Oncology</i> , 2010, 21, 1053-1057.	1.2	41
20	Radioimmunotherapy in Non-Hodgkin Lymphoma: Opinions of Nuclear Medicine Physicians and Radiation Oncologists. <i>Journal of Nuclear Medicine</i> , 2011, 52, 830-838.	5.0	40
21	Radioimmunotherapy in Non-Hodgkin Lymphoma: Opinions of U.S. Medical Oncologists and Hematologists. <i>Journal of Nuclear Medicine</i> , 2010, 51, 987-994.	5.0	36
22	Resin Versus Glass Microspheres for <sup>90</sup> Y Transarterial Radioembolization: Comparing Survival in Unresectable Hepatocellular Carcinoma Using Pretreatment Partition Model Dosimetry. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1334-1340.	5.0	36
23	Systemic administration of 3-bromopyruvate in treating disseminated aggressive lymphoma. <i>Translational Research</i> , 2012, 159, 51-57.	5.0	34
24	Follow-up after radiological intervention in oncology: ECIO-ESOI evidence and consensus-based recommendations for clinical practice. <i>Insights Into Imaging</i> , 2020, 11, 83.	3.4	34
25	<sup>68</sup> Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis. , 2021, 9, e003594.		30
26	Tumor Imaging in Patients with Advanced Tumors Using a New <sup>99m</sup> Tc-Radiolabeled Vitamin B12 Derivative. <i>Journal of Nuclear Medicine</i> , 2014, 55, 43-49.	5.0	29
27	Influence of Bowel Preparation Before <sup>18</sup> F-FDG PET/CT on Physiologic <sup>18</sup> F-FDG Activity in the Intestine. <i>Journal of Nuclear Medicine</i> , 2010, 51, 507-510.	5.0	28
28	Feasibility of integrated CT-liver perfusion in routine FDG-PET/CT. <i>Abdominal Imaging</i> , 2010, 35, 528-536.	2.0	27
29	Perfusion CT best predicts outcome after radioembolization of liver metastases: a comparison of radionuclide and CT imaging techniques. <i>European Radiology</i> , 2014, 24, 1455-1465.	4.5	27
30	Histogram Analysis of CT Perfusion of Hepatocellular Carcinoma for Predicting Response to Transarterial Radioembolization: Value of Tumor Heterogeneity Assessment. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 400-408.	2.0	27
31	Early Treatment Response Evaluation after Yttrium-90 Radioembolization of Liver Malignancy with CT Perfusion. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 747-759.	0.5	26
32	<sup>18</sup> F-FDG PET/CT predicts survival after <sup>90</sup> Y transarterial radioembolization in unresectable hepatocellular carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1215-1222.	6.4	26
33	Theranostics in Interventional Oncology: Versatile Carriers for Diagnosis and Targeted Image-Guided Minimally Invasive Procedures. <i>Frontiers in Pharmacology</i> , 2019, 10, 450.	3.5	26
34	Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET) – The GREPONET Study. <i>Oncologist</i> , 2019, 24, e1082-e1090.	3.7	26
35	Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): Value of <sup>18</sup> F-FDG-PET/CT. <i>European Journal of Radiology</i> , 2012, 81, e19-e25.	2.6	23
36	Radiation dosimetry of <sup>18</sup> F-AzaFol: A first in-human use of a folate receptor PET tracer. <i>EJNMMI Research</i> , 2020, 10, 32.	2.5	23

#	ARTICLE	IF	CITATIONS
37	Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. <i>Annals of Hematology</i> , 2010, 89, 783-787.	1.8	21
38	Head and neck tumors angiogenesis imaging with <sup>68</sup> Ga-NODAGA-RGD in comparison to <sup>18</sup> F-FDG PET/CT: a pilot study. <i>EJNMMI Research</i> , 2020, 10, 47.	2.5	21
39	Liver Perfusion Imaging in Patients with Primary and Metastatic Liver Malignancy. <i>Academic Radiology</i> , 2012, 19, 613-621.	2.5	20
40	Diagnostic Performance of <sup>18</sup> F-FDG PET/CT in Native Valve Endocarditis: Systematic Review and Bivariate Meta-Analysis. <i>Diagnostics</i> , 2020, 10, 754.	2.6	20
41	Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma. <i>Nuclear Medicine Communications</i> , 2011, 32, 1046-1051.	1.1	19
42	First Clinical Results of (d)- <sup>18</sup> F-Fluoromethyltyrosine (BAY 86-9596) PET/CT in Patients with Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1778-1785.	5.0	19
43	Voxel-based <sup>18</sup> F-FET PET segmentation and automatic clustering of tumor voxels: A significant association with IDH1 mutation status and survival in patients with gliomas. <i>PLoS ONE</i> , 2018, 13, e0199379.	2.5	19
44	First-Line Selective Internal Radiation Therapy in Patients with Uveal Melanoma Metastatic to the Liver. <i>Journal of Nuclear Medicine</i> , 2020, 61, 350-356.	5.0	19
45	Combined PET/CT-perfusion in patients with head and neck cancers. <i>European Radiology</i> , 2013, 23, 163-173.	4.5	18
46	Potential use of humanized antibodies in the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1065-1074.	2.4	17
47	Changing PET/CT manifestation of neurolymphomatosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 1244-1244.	6.4	17
48	Internal radiation dosimetry of a <sup>152</sup> Tb-labeled antibody in tumor-bearing mice. <i>EJNMMI Research</i> , 2019, 9, 53.	2.5	17
49	Diagnostic Performance of PET or PET/CT Using <sup>18</sup> F-FDG Labeled White Blood Cells in Infectious Diseases: A Systematic Review and a Bivariate Meta-Analysis. <i>Diagnostics</i> , 2019, 9, 60.	2.6	16
50	Detection Rate of Culprit Tumors Causing Osteomalacia Using Somatostatin Receptor PET/CT: Systematic Review and Meta-Analysis. <i>Diagnostics</i> , 2020, 10, 2.	2.6	16
51	Outpatient Yttrium-90 microsphere radioembolization: assessment of radiation safety and quantification of post-treatment adverse events causing hospitalization. <i>Radiologia Medica</i> , 2020, 125, 971-980.	7.7	16
52	Preclinical Evaluation and Dosimetry of [ <sup>111</sup> In]CHX-DTPA-scFv78-Fc Targeting Endosialin/Tumor Endothelial Marker 1 (TEM1). <i>Molecular Imaging and Biology</i> , 2020, 22, 979-991.	2.6	15
53	Increased <sup>18</sup> F-FDG signal recovery from small physiological structures in digital PET/CT and application to the pituitary gland. <i>Scientific Reports</i> , 2020, 10, 368.	3.3	15
54	The value of <sup>18</sup> F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas. <i>Laryngoscope</i> , 2010, 120, 937-944.	2.0	14

#	ARTICLE	IF	CITATIONS
55	Pulmonary Lymphangitic Carcinomatosis: Diagnostic Performance of High-Resolution CT and <sup>18</sup> F-FDG PET/CT in Correlation with Clinical Pathologic Outcome. <i>Journal of Nuclear Medicine</i> , 2020, 61, 26-32.	5.0	14
56	Added value of <sup>18</sup> F-FDG PET/CT in a SARS-CoV-2-infected complex case with persistent fever. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2036-2037.	6.4	12
57	Imaging angiogenesis in atherosclerosis in large arteries with <sup>68</sup> Ga-NODAGA-RGD PET/CT: relationship with clinical atherosclerotic cardiovascular disease. <i>EJNMMI Research</i> , 2021, 11, 71.	2.5	12
58	Pulmonary Hypertrophic Osteoarthropathy in a Patient With Nonsmall Cell Lung Cancer: Diagnosis With FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2006, 31, 624-626.	1.3	11
59	Monte Carlo <sup>90</sup> Y PET/CT dosimetry of unexpected focal radiation-induced lung damage after hepatic radioembolisation. <i>Physics in Medicine and Biology</i> , 2020, 65, 235014.	3.0	10
60	Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma. <i>Cancers</i> , 2022, 14, 1162.	3.7	9
61	Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component. <i>European Radiology</i> , 2011, 21, 256-264.	4.5	8
62	Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 85-88.	1.7	8
63	Impact of DOTA Conjugation on Pharmacokinetics and Immunoreactivity of [ <sup>177</sup> Lu]Lu-1C1m-Fc, an Anti TEM-1 Fusion Protein Antibody in a TEM-1 Positive Tumor Mouse Model. <i>Pharmaceutics</i> , 2021, 13, 96.	4.5	8
64	Simplified patient-specific renal dosimetry in <sup>177</sup> Lu therapy: a proof of concept. <i>Physica Medica</i> , 2021, 92, 75-85.	0.7	8
65	Tumor Growth Rate to Predict the Outcome of Patients with Neuroendocrine Tumors: Performance and Sources of Variability. <i>Neuroendocrinology</i> , 2021, 111, 831-839.	2.5	7
66	Template directed synthesis of antibody Fc conjugates with concomitant ligand release. <i>Chemical Science</i> , 2022, 13, 3965-3976.	7.4	6
67	Overview of the RGD-Based PET Agents Use in Patients With Cardiovascular Diseases: A Systematic Review. <i>Frontiers in Medicine</i> , 2022, 9, .	2.6	5
68	Arterial Therapies of Non-Colorectal Liver Metastases. <i>Visceral Medicine</i> , 2015, 31, 414-422.	1.3	4
69	Impact of prophylactic cranial irradiation and hippocampal sparing on <sup>18</sup> F-FDG brain metabolism in small cell lung cancer patients. <i>Radiotherapy and Oncology</i> , 2021, 158, 200-206.	0.6	4
70	Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody responses in humans, a RAYS-based analysis. <i>International Journal of Oncology</i> , 2011, 39, 287-94.	3.3	3
71	Prevalence and clinical significance of incidental <sup>18</sup> F-FDG uptake in the pituitary. <i>Clinical and Translational Imaging</i> , 2020, 8, 237-242.	2.1	3
72	From Theranostics to Immunotheranostics: the Concept. <i>Nuclear Medicine and Molecular Imaging</i> , 2020, 54, 81-85.	1.0	3

#	ARTICLE	IF	CITATIONS
73	Prevalence of physiological uptake in the pancreas on somatostatin receptor-based PET/CT: a systematic review and a meta-analysis. <i>Clinical and Translational Imaging</i> , 2021, 9, 353-360.	2.1	3
74	Biological evaluation of new TEM1 targeting recombinant antibodies for radioimmunotherapy: In vitro, in vivo and in silico studies. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 158, 233-244.	4.3	3
75	Copper-64-Labeled 1C1m-Fc, a New Tool for TEM-1 PET Imaging and Prediction of Lutetium-177-Labeled 1C1m-Fc Therapy Efficacy and Safety. <i>Cancers</i> , 2021, 13, 5936.	3.7	2
76	First experience of durable cytoreduction in chronic lymphoid leukemia with 177Lu-DOTATATE. <i>Medical Oncology</i> , 2019, 36, 41.	2.5	1
77	Transarterial Radioembolization for the Treatment of Advanced Hepatocellular Carcinoma Invading the Right Atrium. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1712-1715.	2.0	1
78	Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases. <i>Frontiers in Oncology</i> , 2021, 11, 704295.	2.8	1
79	Functional and Radiological Imaging of Neuroendocrine Neoplasms. , 2021, , 29-53.		1
80	Lymphoma: Management Using PET/CT. , 2014, , 257-260.		0
81	Abstract 1304: AbYlink™: A site-selective labeling method for preclinical imaging of therapeutic antibodies. , 2021, , .		0
82	Acute lymphoblastic leukaemia presenting as euglycaemic ketoacidosis in a patient with type 1 diabetes. <i>Lancet Haematology</i> , 2021, 8, e534.	4.6	0
83	Gastrointestinal Stromal Tumors. , 2008, , 385-389.		0
84	Additional value of tumour growth rate (TGR) in patients (pts) diagnosed with well-differentiated neuroendocrine tumours (NETs) achieving RECIST-defined stable disease (SD): Subgroup analysis of the GREPONET study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4094-4094.	1.6	0
85	Case Report: Vasculitis Triggered by SIRT in a Patient With Previously Untreated Cholangiocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 755750.	2.8	0